Full-Time

Senior Data Scientist

Updated on 7/29/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

On-site role in Hyderabad, India.

Category
Data & Analytics (1)
Required Skills
Data Science
Machine Learning

Get referred to Amgen

Find people who can refer or advise you

Requirements
  • Doctorate degree with 4+yrs in Pharmacometrics, Quantitative Pharmacology, Pharmacokinetics, Bioengineering, Biomedical Engineering, Computational Biology, Applied Mathematics, Statistics, Data Science, or a related field
  • Or
  • Master's degree and 8+years of directly related experience
Responsibilities
  • Develop and apply PBPK, TMDD, PK/PD, exposure-response, and related quantitative models for biologics discovery and translational questions
  • Translate complex scientific information into quantitative assumptions, scenarios, and simulations that support model-informed decision-making
  • Build reproducible workflows for parameter estimation, model calibration, sensitivity and uncertainty analysis, documentation, and review
  • Apply statistical, machine learning, or Bayesian methods where appropriate to support parameter inference, model updating, and scenario analysis
  • Partner with experimental and translational teams to align modeling plans, interpret results, and identify fit-for-purpose data needs
  • Communicate modeling assumptions, limitations, uncertainty, findings, and recommendations clearly through reports, visualizations, and presentations
  • Contribute to scalable model-informed drug design practices and reusable modeling frameworks that can support biologics discovery programs
Desired Qualifications
  • Experience developing PBPK, TMDD, PK/PD, exposure-response, quantitative systems pharmacology, or other mechanistic models for biologics or therapeutic discovery
  • Strong understanding of biologics pharmacology, target-mediated drug disposition, translational scaling, and cross-species extrapolation
  • Experience working with scientific, preclinical, translational, or literature-derived data sources in a data-governed environment
  • Proficiency with scientific computing and modeling tools such as R, Python, MATLAB, NONMEM, Monolix, mrgsolve, Stan, PyMC, SimBiology, or related platforms
  • Experience with model calibration, parameter estimation, sensitivity analysis, uncertainty quantification, simulation-based study design, and model documentation
  • Ability to translate quantitative models, assumptions, and uncertainty into clear recommendations for cross-functional scientific stakeholders
  • Experience supporting biologics, antibodies, protein therapeutics, translational science, quantitative pharmacology, or early drug discovery
  • Familiarity with reproducible scientific computing practices, including version control, workflow automation, code review, testing, documentation, and data provenance
  • Strong scientific communication skills, with peer-reviewed publications in venues such as CPT: Pharmacometrics & Systems Pharmacology, Journal of Pharmacokinetics and Pharmacodynamics, Clinical Pharmacokinetics, or comparable journals; candidates are encouraged to highlight representative publications on their resume

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • A broad pipeline targets heart disease, obesity, rare disease, inflammation, and cancer.
  • Global reach across roughly 100 countries supports scale and diversification.
  • Legacy cash flows from mature biologics fund new medicine development.

What critics are saying

  • Enbrel faces pricing pressure after Colorado's 70% price-cap challenge.
  • Recent Corlanor and Sensipar recalls expose manufacturing and quality-control weaknesses.
  • Biosimilar competition threatens mature biologics and compresses future margins.

What makes Amgen unique

  • Amgen combines biologics discovery, manufacturing, and commercialization under one integrated platform.
  • Its portfolio spans oncology, cardiovascular, inflammation, bone health, and rare disease.
  • Human genetics and biology guide its drug discovery strategy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.